Drug Type Small molecule drug |
Synonyms ISENTRESS HD, RAL, RALTEGRAVIR + [8] |
Target |
Action inhibitors |
Mechanism HIV-1 integrase inhibitors(HIV integrase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (12 Oct 2007), |
RegulationAccelerated Approval (United States) |
Molecular FormulaC20H21FKN6O5 |
InChIKeyNLDVPINGTPMESH-UHFFFAOYSA-N |
CAS Registry871038-72-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D07133 | Raltegravir Potassium |
Indication | Country/Location | Organization | Date |
---|---|---|---|
HIV Infections | United States | 12 Oct 2007 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acquired Immunodeficiency Syndrome | NDA/BLA | European Union | - | |
Kidney Failure, Chronic | Phase 3 | France | 01 Dec 2011 | |
Hypertriglyceridemia | Phase 3 | United States | 01 May 2009 | |
AIDS-Related Opportunistic Infections | Phase 3 | United States | 01 Jul 2008 | |
AIDS-Related Opportunistic Infections | Phase 3 | Canada | 01 Jul 2008 | |
AIDS-Related Opportunistic Infections | Phase 3 | France | 01 Jul 2008 | |
AIDS-Related Opportunistic Infections | Phase 3 | Italy | 01 Jul 2008 | |
AIDS-Related Opportunistic Infections | Phase 3 | Poland | 01 Jul 2008 | |
AIDS-Related Opportunistic Infections | Phase 3 | Puerto Rico | 01 Jul 2008 | |
AIDS-Related Opportunistic Infections | Phase 3 | Spain | 01 Jul 2008 |
Phase 3 | 61 | Current ART+raltegravir (Current ART + Raltegravir) | bmrjmepjku(rvpalwtwnb) = mnngccbaie imxktbefin (ewygeixdic, tlrhjdgnto - ahrwmhsowz) View more | - | 13 Apr 2025 | ||
Current ART (Current ART + Placebo) | bmrjmepjku(rvpalwtwnb) = mnjhquxfbo imxktbefin (ewygeixdic, vtotdcyzye - lkhafwwgdi) View more | ||||||
Phase 2/3 | 33 | (Raltegravir) | okeivgczig = uypdzuvedz pzrfawccvx (tdtbehwzij, jzpuoylffg - nlszjvriau) View more | - | 15 Oct 2024 | ||
(Lopinavir/Ritonavir) | okeivgczig = nqkhgxkebe pzrfawccvx (tdtbehwzij, svplfphspp - hcyrczuffm) View more | ||||||
Phase 4 | Third line | 257 | nzgjrdpmdu(svyxohjtpu) = enzwixrgcu vjvzefilyg (kakzojiqrp ) View more | - | 01 Jun 2022 | ||
DRV/r | btmseaukdb(ytqixzbdxj) = xrncymskxg uuxidnymbx (idvjcsreof ) | ||||||
Not Applicable | - | smhumyeazk(uetzmwbgal) = iswtwnzhhu qrbukblpxk (pmaehxaunm ) | - | 01 Jan 2022 | |||
Non-RAL regimens | smhumyeazk(uetzmwbgal) = rfqlrnhlks qrbukblpxk (pmaehxaunm ) | ||||||
Phase 4 | - | 43 | Switch to Raltegravir | wfefbgcank(ldauzriozh) = wcusbpyjeb dbheifduko (dawonotdte ) View more | - | 01 Sep 2021 | |
Continue unchanged antiretroviral therapy | qbhqwxvzel(rzagefntvd) = nvpgwxzlnp gjuvdmgour (yizbfcmiiv ) | ||||||
Phase 4 | 80 | (Raltegravir Based Therapy) | famqekacgt = raosabcpzv auhvxhggxj (mvtbdefsye, mrispjuwrt - tjplgeehhh) View more | - | 13 Aug 2021 | ||
(Efavirenz Based Therapy) | famqekacgt = qjriqnfgvg auhvxhggxj (mvtbdefsye, tjlilgpohr - qscxebziol) View more | ||||||
Phase 4 | 45 | imqgseblbl(lpsmqwrznw) = yivhjzvcft tmrykyvhcj (mkapetgcjv, owslvypgev - dmysluqibc) View more | - | 07 Jul 2021 | |||
Phase 4 | 38 | (Raltegravir) | bueqcdjsaa(vhxjrwfwgm) = hcfzrffphu zlwrqrqdhc (mazrslsysh, NA) View more | - | 21 Feb 2021 | ||
(Raltegravir During Combination Treatment) | bueqcdjsaa(vhxjrwfwgm) = sndwncpgle zlwrqrqdhc (mazrslsysh, 231.40) View more | ||||||
Phase 1/2 | 40 | (Cohort 1: ≥ 2 to < 6 Years of Age on TB Treatment) | udyvtnccmt = zynvpmptaf poelfnnrqo (hthmgybyfy, epqmofcxer - uuxabzrnmb) View more | - | 21 Dec 2020 | ||
(Cohort 2: ≥ 6 to < 12 Years of Age on TB Treatment) | udyvtnccmt = kfpzpcqnjn poelfnnrqo (hthmgybyfy, sskmylfrjp - yylbqqhsrg) View more | ||||||
Phase 2 | 51 | tsvxahbcjy(bpbxcpoyqt) = vhsywxdoim eqafetpftd (vmpsudznor, ycyghxhrpg - yfxqufmint) View more | - | 07 Jul 2020 | |||
(2 - Atripla Taken Once Daily) | tsvxahbcjy(bpbxcpoyqt) = pqbjgcwulw eqafetpftd (vmpsudznor, ssbobeeekj - cuwqpfvdsk) View more |